Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012711 | 0.94 | MET (0.39) | METHRH3CHRM2CHRM1CHRM3 | |
| SCHEMBL31080558 | 0.87 | CHRM2 (0.39) | KAT2BCHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL31080112 | 0.87 | CHRM2 (0.39) | KAT2BCHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL31080294 | 0.84 | MET (0.33) | METPDGFRBPDGFRACHRM2CHRM1 | |
| SCHEMBL19511002 | 0.83 | PDGFRB (0.40) | PDGFRBPDGFRA | |
| SCHEMBL19510571 | 0.83 | PDGFRB (0.43) | PDGFRBPDGFRA | |
| SCHEMBL3509515 | 0.82 | PDGFRB (0.44) | PDGFRBPDGFRA | |
| SCHEMBL20772699 | 0.80 | CDK2 (0.39) | PDGFRBPDGFRA | |
| SCHEMBL31080708 | 0.80 | CHRNA3 (0.36) | — | |
| SCHEMBL9965911 | 0.79 | CHRNB2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |